• Evogene will hold its annual general meeting on Sept. 4, 2026 in Rehovot, Israel.
• Shareholders will vote on competing board slates: a seven-member slate backed by the board or a four-member slate nominated by Pure Capital shareholders.
• An amendment is proposed to lift authorized share capital by NIS 24 million to NIS 30 million, representing 150,000,000 ordinary shares.
• A reverse share split framework is up for approval, allowing a ratio between 1-for-2 and 1-for-15 at the board’s discretion within 18 months.
• Kost Forer Gabbay & Kasierer, an Ernst & Young member firm, is proposed for reappointment as independent auditor for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-003741), on July 31, 2026, and is solely responsible for the information contained therein.